diethoxyphosphoryloxymethyl butanoate

butyroyloxymethyl-diethyl phosphate antitumor cpd; structure in first source; do not confuse with AN 7 peptide complex

Also Known As:

AN-7 diethylphosphate; AN-7 phosphate cpd; butyroyloxymethyl diethylphosphate; butyroyloxymethyl-diethyl phosphate

Networked: 8 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Butyrates: 2613
      - diethoxyphosphoryloxymethyl butanoate: 8
- Organophosphorus Compounds: 300
  - diethoxyphosphoryloxymethyl butanoate: 8
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Butyrates: 2613
      - diethoxyphosphoryloxymethyl butanoate: 8

Experts

1.	Nudelman, Abraham: 7 articles (01/2018 - 08/2005)
2.	Rephaeli, Ada: 7 articles (01/2018 - 08/2005)
3.	Tarasenko, Nataly: 5 articles (01/2018 - 08/2005)
4.	Cutts, Suzanne M: 4 articles (02/2012 - 08/2005)
5.	Phillips, Don R: 4 articles (02/2012 - 08/2005)
6.	Inbal, Aida: 3 articles (02/2012 - 01/2008)
7.	Entin-Meer, Michal: 3 articles (01/2008 - 08/2005)
8.	Kessler-Icekson, Gania: 2 articles (02/2012 - 01/2012)
9.	Levovich, Inesa: 2 articles (10/2006 - 08/2005)
10.	Goldfeiz, Neta: 1 article (01/2018)

Related Diseases

1.	Cardiotoxicity 02/01/2012 - "The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) has been shown to synergize doxorubicin (Dox) anticancer activity while attenuating its cardiotoxicity. " 04/11/2012 - "Butyroyloxymethyl diethylphosphate (AN-7) is a prodrug of butyric acid effective in reducing cardiotoxicity caused by chemotherapy. "
2.	Neoplasms (Cancer) 01/01/2012 - "Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor." 01/01/2008 - "We sought to characterize the antiangiogenic and antimetastatic activities of two lead prodrugs, pivaloyloxymethyl butyrate (AN-9) and butyroyloxymethyl-diethyl phosphate (AN-7) in murine cancer models. "
3.	Carcinoma (Carcinomatosis) 01/01/2012 - "The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. " 10/01/2006 - "To investigate the anticancer activity and mode of action of butyroyloxymethyl-diethyl phosphate (AN-7), a prodrug of butyric acid and formaldehyde, as a single agent and in combination with doxorubicin in human carcinoma MCF-7 and the multidrug resistant MCF-7 Dx cell lines. "
4.	Corneal Neovascularization 07/01/2017 - "To examine whether butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, inhibits chemically induced corneal neovascularization (NV) in mice. " 07/01/2017 - "Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model."
5.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/01/2018 - "We previously found that the novel histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) had greater selectivity against cutaneous T-cell lymphoma (CTCL) than SAHA. "

Related Drugs and Biologics

1.	Prodrugs
2.	Butyric Acid (Butanoic Acid)
3.	Histone Deacetylase Inhibitors
4.	Doxorubicin (Adriamycin)
5.	Histone Deacetylases (Histone Deacetylase)
6.	Formaldehyde (Formol)
7.	Butyrates (Butyrate)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)